Cargando…
Antibody-Drug Conjugates and Immunotoxins From Pre-Clinical Development to Therapeutic Applications /
The concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal a...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York, NY :
Springer New York : Imprint: Humana,
2013.
|
| Edición: | 1st ed. 2013. |
| Colección: | Cancer Drug Discovery and Development,
|
| Temas: | |
| Acceso en línea: | Texto Completo |
Tabla de Contenidos:
- Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins
- Antibody-Drug Conjugate Development
- Components of ADC Development: Assay Methodologies and Challenges
- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates
- Predictive Biomarkers for Antibody-Drug Conjugates
- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates
- Linker Technology and Impact of Linker Design on ADC Properties
- Antibody-drug conjugates for the treatment of B-cell malignancies
- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies
- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies
- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer
- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)
- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer
- EphA2 Immunoconjugate
- Anti-PSMA Antibody-Drug Conjugates
- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine
- Studies on the Metabolism of Antibody-Drug Conjugates
- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu
- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors
- Index.